Attention GSK ADR Holders: Important Information Regarding a Securities Class Action Lawsuit
New York, NY – In an investor alert issued on March 7, 2025, Rosen Law Firm, a leading global investor rights law firm, reminded purchasers of American Depositary Receipts (ADRs) of GSK plc (NYSE:GSK) between February 5, 2020, and August 14, 2022, that they may be entitled to compensation without any out-of-pocket costs or fees if they were affected by certain allegations involving the company. The deadline to apply to serve as the lead plaintiff in this class action is fast approaching.
What Happened?
According to the allegations in the lawsuit, during the Class Period, GSK plc and certain of its executives allegedly made false and misleading statements and failed to disclose material information about the company’s business, operations, and prospects. Specifically, the lawsuit alleges that the defendants failed to disclose that the company was facing increased regulatory scrutiny and potential penalties related to its marketing and sales practices for certain pharmaceutical products.
Who Is Affected?
If you purchased GSK ADRs during the Class Period, you may be entitled to compensation. The Class Period refers to the time frame between February 5, 2020, and August 14, 2022. This includes both U.S. and Canadian purchasers of GSK ADRs.
What Does This Mean for Me?
If you purchased GSK ADRs during the Class Period, you may be able to recover your losses through a contingency fee arrangement. A securities class action lawsuit is a type of legal proceeding where a large group of investors with similar claims come together to bring a lawsuit against a company and its executives. By joining the class action, you do not need to pay any upfront costs or fees to participate. Instead, the law firm representing the class, in this case, Rosen Law Firm, will cover the costs and fees and will only be paid if the case is successful.
What Does This Mean for the World?
This lawsuit is an example of the importance of investor protection and the role of securities class action lawsuits in holding companies and their executives accountable for misrepresentations and violations of securities laws. The lawsuit may also lead to increased transparency and disclosures from GSK plc regarding its regulatory issues and potential penalties.
Lead Plaintiff Deadline
It’s important to note that the deadline to apply to serve as the lead plaintiff in this class action is April 7, 2025. The lead plaintiff is the representative party for all other class members in the lawsuit. The lead plaintiff plays a significant role in the litigation process, helping to direct the lawsuit and make important decisions. If you purchased GSK ADRs during the Class Period and wish to serve as the lead plaintiff, it’s essential that you take action before the deadline.
Contact Information
If you purchased GSK ADRs during the Class Period and wish to discuss your recovery options or have any questions regarding this announcement or the class action, please contact the Rosen Law Firm by calling Phillip Kim, Esq. or Kevin Chan, Esq. at 866-767-3653 or via email at [email protected] or [email protected]. For more information about the lawsuit, please visit
About Rosen Law Firm: Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and other complex litigation.
Conclusion
If you purchased GSK ADRs between February 5, 2020, and August 14, 2022, and believe that you may have been affected by the allegations in the lawsuit, it’s essential to take action before the April 7, 2025, lead plaintiff deadline. By joining the class action, you may be able to recover your losses without any upfront costs or fees. For more information, please contact Rosen Law Firm at 866-767-3653 or via email at [email protected] or [email protected].
This announcement is not a solicitation for securities claims involving GSK plc. The Rosen Law Firm is not filing a class action lawsuit and is not acting as counsel in the above-mentioned lawsuit. If you wish to serve as the lead plaintiff, you must retain counsel unaffiliated with the Rosen Law Firm.
